이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

우울증에 대한 NH102를 평가하는 II 상 연구 (NH102-21)

2026년 9월 20일 업데이트: Jiangsu Nhwa Pharmaceutical Co., Ltd.

우울증 치료에서 NH102의 효능 및 안전성을 평가하기위한 다기관, 무작위, 이중 맹인, 이중 더미, 위약 및 활성 제어 단계 II 임상 시험.

This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine . It is designed to preliminarily assess the efficacy and safety of NH102 in patients with major depressive disorder and to provide the basis for the design of Phase III clinical trials.

연구 개요

상세 설명

This trial consists of three periods: a screening period (up to 2 weeks), a double-blind treatment period (6 weeks), and a tapering-off period/safety follow-up (1 week). The screening period may last up to 14 days and a minimum of 1 day.

Baseline assessments will be conducted prior to randomization to confirm the eligibility of participants. A total of 240 patients with depression will be randomly assigned in a 1:1:1:1:1 ratio to three experimental drug groups (10 mg, 20 mg, and 30 mg), one active control group (duloxetine hydrochloride capsules 60 mg ), or one placebo group. The double-blind treatment period will last for 6 weeks, during which participants will take the assigned medications according to the specified dosing regimen and will be followed up at the end of weeks 1, 2, 4, and 6. After the treatment period, participants will enter a 1-week tapering-off period and will undergo safety follow-up at the end of week 7.

연구 유형

중재적

등록 (실제)

243

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Anhui
      • Hefei, Anhui, 중국, 230000
        • Anhui Mental Health Center
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100096
        • Beijing Huilongguan Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, 중국, 400036
        • Chongqing Mental Health Center
    • Fujian
      • Xiamen, Fujian, 중국, 361012
        • Xiamen Xianyue Hospital
    • Guangdong
      • Guangzhou, Guangdong, 중국, 510370
        • The Affiliated Brain Hospital of Guangzhou Medical University
      • Shenzhen, Guangdong, 중국, 518118
        • Shenzhen Kangning Hospital
    • Hebei
      • Baoding, Hebei, 중국, 071000
        • Hebei Mental Health Hospital
    • Henan
      • Xinxiang, Henan, 중국, 453000
        • The Second Affiliated Hospital of Henan Medical University
      • Zhumadian, Henan, 중국, 463000
        • Zhumadian Second People's Hospital
    • Hunan
      • Changsha, Hunan, 중국, 410007
        • Hunan Second people's Hospital
    • Jiangsu
      • Suzhou, Jiangsu, 중국, 215000
        • Suzhou Guangji Hospital
      • Wuxi, Jiangsu, 중국, 214000
        • Wuxi Mental Health Center
    • Jiangxi
      • Nanchang, Jiangxi, 중국, 330038
        • Nanchang Mental Health Center
    • Jilin
      • Siping, Jilin, 중국, 136000
        • Jilin Provincial Neuropsychiatric Hospital
    • Shandong
      • Jinan, Shandong, 중국, 250014
        • Shongdong Mental Health Center
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, 중국, 200030
        • Shanghai Mental Health Center
    • Shanxi
      • Taiyuan, Shanxi, 중국, 030000
        • Frist Hospital of Shanxi Medical University
      • Xi’an, Shanxi, 중국, 710000
        • Xi'an Mental Health Center
    • Sichuan
      • Chengdu, Sichuan, 중국, 610072
        • Sichuan Provincial People's Hospital
      • Chengdu, Sichuan, 중국, 610000
        • The Fourth People's Hospital of Chengdu
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, 중국, 300000
        • Tianjin Anding Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310003
        • Hangzhou Seventh People's Hospital
      • Huzhou, Zhejiang, 중국, 313000
        • Huzhou Third Municipal Hospital
      • Ningbo, Zhejiang, 중국, 315000
        • The Affiliated Kangning Hospital of Ningbo University

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Male and female outpatients aged 18-65 years (inclusive).
  • Diagnosis of Major Depressive Disorder (MDD) according to DSM-5 criteria ( without psychotic features).
  • Hamilton Depression Rating Scale (HAM-D17) total score ≥ 22 at screening and baseline visits, with item 1 (depressed mood) score ≥ 2.
  • Clinical Global Impression-Severity (CGI-S) score ≥ 4 at screening and baseline.
  • Negative pregnancy test for women of childbearing potential.
  • Willingness to use effective contraception during the trial and for 3 months after the last dose.
  • Voluntary participation and signed informed consent.

Exclusion Criteria:

  • Duration of the current depressive episode in first-episode patients < 3 months.
  • Treatment-resistant depression (failure of ≥ 2 adequate antidepressant treatments).
  • Other psychiatric disorders (e.g., schizophrenia, bipolar disorder, anxiety disorders).
  • History of severe neurological diseases, epilepsy, or significant head trauma.
  • Unstable or severe cardiovascular, gastrointestinal, or endocrine diseases.
  • History of malignancy within the past 2 years.
  • History of increased intraocular pressure or untreated narrow-angle glaucoma.
  • Abnormal thyroid function not adequately controlled.
  • History of severe drug allergies or hypersensitivity to duloxetine or excipients.
  • Suicide attempt within the past year or significant suicide risk.
  • Substance abuse within the past year or positive at screening drug test.
  • Alcohol abuse (≥ 14 units/week) within the past year.
  • Previous treatment with duloxetine without adequate response.
  • Normative use of antidepressants within 2 weeks prior to screening.
  • Use of CYP2D6 or CYP1A2 potent inhibitors/inducers within 2 weeks prior to screening.
  • Participation in another clinical trial within the past 3 months.
  • Any condition deemed unsuitable by the investigator.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: 위약

Matched dosing regimen.Twice daily for 6 weeks, followed by a 1-week tapering period.

실험적: NH102 10mg

5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

실험적: NH102 20mg

5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

실험적: NH102 30mg

5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

활성 비교기: 둘록세틴 히드로 클로라이드 장내 캡슐

30 mg twice daily for 6 weeks, followed by a 1-week tapering period.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
17 items Hamilton Depression Scales (HAM-D17)
기간: 6 Weeks

Changes from baseline in the 17 items Hamilton Depression Scales (HAM-D17) total score at the end of treatment.

HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50. Higher scores indicate a worse outcome.

6 Weeks

2차 결과 측정

결과 측정
측정값 설명
기간
17 items Hamilton Depression Scales (HAM-D17)
기간: Week 2 and 4

Changes from baseline in the 17 items Hamilton Depression Scales (HAM-D17) total score at Week 2 and 4.

HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50. Higher scores indicate a worse outcome.

Week 2 and 4
Montgomery- Åsberg Depression Rating Scale(MADRS)
기간: 6 Weeks

Changes from baseline in the 10-items Montgomery- Åsberg Depression Scales (MADRS) total score at Week 2, Week 4 and the end of treatment.

MADRS is a standardized, clinician-administered rating scale that assesses 10 items characteristically associated with major depression. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

6 Weeks
Clinical Global Impression-Improvement (CGI-I)
기간: 6 Weeks

Changes from baseline in the CGI-I score at the end of treatment.

The Clinical Global Impression-Improvement (CGI-I) scale is a clinician-rated instrument designed to assess the overall improvement or worsening of a patient's condition relative to a baseline state. The following one query is rated on a seven-point scale: "Compared to the patient's condition at admission to the project, this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."

6 Weeks
Clinical Global Impression-Severity (CGI-S)
기간: 6 Weeks

Changes from baseline in the Clinical Global Impression-Severity (CGI-S) score at the end of treatment.

The CGI-S asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.

6 Weeks
Hamilton Anxiety Rating Scale (HAM-A)
기간: 6 Weeks

Changes from baseline in the HAM-A total score at the end of treatment.

The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered assessment tool to measure the severity of anxiety symptoms. It consists of 14 items, each evaluating a specific symptom of anxiety, such as anxious mood, tension, fears, and somatic complaints. Each item is scored on a scale from 0 (None) to 4 ( Very severe. grossly disabling ), with the total score ranging from a minimum of 0 to a maximum of 56. Higher scores indicate greater severity of anxiety symptoms, reflecting a worse clinical outcome.

6 Weeks
Dimensional Anhedonia Rating Scale (DARS)
기간: 6 Weeks

Change from baseline in Dimensional Anhedonia Rating Scale (DARS) total score at the end of treatment.

The DARS is a self-report scale that measures anhedonia across the following 4 domains: hobbies/past-times, food/drinks, social activities, and sensory experiences. Within each domain, participants are required to provide at least two of their own examples of what they find rewarding. Subsequently, participants answer a set of standardized questions about desire, motivation, effort and consummatory pleasure for the examples provided. Responses were based on a 5-point Likert scale (Not at all=0; Slightly=1; Moderately=2; Mostly=3; Very Much=4), with the total score ranging from a minimum of 0 to a maximum of 68. A higher score reflects a better outcome.

6 Weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 12월 4일

기본 완료 (실제)

2025년 7월 30일

연구 완료 (실제)

2025년 9월 12일

연구 등록 날짜

최초 제출

2025년 2월 16일

QC 기준을 충족하는 최초 제출

2025년 2월 19일

처음 게시됨 (실제)

2025년 2월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 22일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 20일

마지막으로 확인됨

2025년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • NH102-21

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다